Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent

Mark Welliver¹,³
John McDonough¹,³
Nicholas Kalynych¹,²,³
Robert Redfern³

¹University of North Florida, Nurse Anesthetist Program, Jacksonville, Florida, USA; ²Shands Jacksonville, Perioperative Services, Jacksonville, Florida, USA; ³University of Florida, Department of Anesthesiology, Jacksonville, Florida, USA

Abstract: Neuromuscular blockade, induced by neuromuscular blocking agents, has allowed prescribed immobility, improved surgical exposure, optimal airway management conditions, and facilitated mechanical ventilation. However, termination of the effects of neuromuscular blocking agents has, until now, remained limited. A novel cyclodextrin encapsulation process offers improved termination of the paralytic effects of aminosteroidal non-depolarizing neuromuscular blocking agents. Sugammadex sodium is the first in a new class of drug called selective relaxant binding agents. Currently, in clinical trials, sugammadex, a modified gamma cyclodextrin, has shown consistent and rapid termination of neuromuscular blockade with few side effects. The pharmacology of cyclodextrins in general and sugammadex in particular, together with the results of current clinical research are reviewed. The ability of sugammadex to terminate the action of neuromuscular blocking agents by direct encapsulation is compared to the indirect competitive antagonism of their effects by cholinesterase inhibitors. Also discussed are the clinical implications that extend beyond fast, effective reversal, including numerous potential peri-operative benefits.

Keywords: modified cyclodextrin, selective relaxant binding agent (SRBA), sugammadex, encapsulation, muscle relaxants, neuromuscular blockade reversal

Introduction

Since the introduction of curare, neuromuscular blocking agents (NMBAs) have allowed us to immobilize patients and improve medical and surgical interventions (Bohm 1912; Griffith and Johnson 1942). The synthesis and development of new NMBAs have produced agents that are close to ideal. Unfortunately, NMBA reversal agents have not been improved upon. The cholinesterase inhibitor drugs first used to reverse curare currently remain the standard for reversing all NMBAs. The indirect action of cholinesterase inhibitors is limited in its ability to reverse neuromuscular blockade, and is associated with numerous side effects. A new class of drugs, selective relaxant binding agents (SRBAs), has the potential to overcome the limitations of cholinesterase inhibitors.

The first SRBA to be introduced is sugammadex (sugammadex sodium, generic, Organon International, a part of Schering-Plough Corporation, Oss, The Netherlands), a modified gamma cyclodextrin (CD) with the chemical formula C72H104Na8O48S8 currently in phase III clinical trials. Unlike the cholinesterase inhibitors, which indirectly and competitively antagonize NMBAs by increasing acetylcholine (ACh), sugammadex acts by directly encapsulating, binding, and inactivating NMBAs (Figure 1).

Conventional neuromuscular blockade reversal

Cholinesterase inhibitors act indirectly against the effects of NMBAs by inactivating the enzyme acetylcholinesterase (AChE) which is responsible for the breakdown
of ACh. Acetylcholine levels then increase dramatically, displacing the NMBA molecules from the nicotinic receptors. Thus, NMBA s are not inactivated or broken down by cholinesterase inhibitors. They are only displaced from the site of action, the nicotinic receptor. The two cholinesterase inhibitors most often used in clinical practice are edrophonium and neostigmine, which form reversible, non-covalent attachments to the anionic site or esteratic site on the AChE molecule. Their duration of action is 60 minutes or less. AChE activity returns to normal after the detachment and metabolism of cholinesterase inhibitors. The temporary increase in ACh then returns to normal levels. NMBA molecules still present after normalization of ACh levels may successfully compete for the nicotinic receptor and re-exert their neuromuscular blocking effects. Recurrence of paralysis (recurarization) is usually only a risk with long-acting NMBA s, although it has been reported with intermediate duration NMBA s (Singh et al 1982; Baillard et al 2000; Debaene et al 2003). Similarly, incomplete displacement (partial reversal) of NMBA s by cholinesterase inhibitors may result in residual paralysis (Hayes et al 2001; Appelboam et al 2003; Kirkegaard et al 2002; Murphy et al 2005; Murphy 2006).

Residual paralysis
The risks of residual paralysis include: dysphagia, hypoventilation, weakened hypoxic drive, impaired coughing, compromised pharyngeal and laryngeal function and pulmonary complications (Berg et al 1997; Eriksson 1999; Tramer and Fuchs-Buder 1999; Eikermann et al 2006). The primary concern in patients with residual paralysis is airway protection and adequate ventilation. Atelectasis may occur intra-operatively due to patient position, positive pressure ventilation, and hypoventilation, and is compounded in the post-operative period by any degree of residual paralysis. The residual presence of volatile anesthetics, benzodiazepines, and narcotics in the tissue compartments contribute to post-operative hypoventilation. Hypoventilation coupled with residual paralysis places a patient in less than optimal circumstances (Eriksson 1999).

Another drawback of cholinesterase inhibitors is their effects on ACh levels are not limited to the nicotinic junction. Generalized increases in ACh throughout the body causes pronounce side effects. Parasympathetic effects predominate when ACh is increased, leading to cardiovascular, pulmonary, gastrointestinal, and neurological sequelae. Side effects of cholinesterase inhibitors include: bradycardia, bronchospasm, increased airway secretions, nausea, vomiting, increased peristalsis, increased urination, muscle cramps/spasms, miosis, vision disturbances, and convulsions (Neostigmine Package Insert 2002). Anti-cholinergic drugs are therefore given concomitantly with cholinesterase inhibitors to attenuate their parasympathetic effects. These anti-cholinergic drugs are partially effective in this respect but exert their own side effects including: cardiac arrhythmias, tachycardia, QT prolongation, nausea, vomiting, constipation, urinary retention, severe allergic reactions, dry mouth, mydriasis, and confusion (Glycopyrrolate Package Insert 2002).

In contrast, a new concept of NMBA inactivation by SRBA encapsulation rather than competitive antagonism has been shown to be fast, effective, and safe for the reversal of neuromuscular blockade in clinical trials to date with few side effects. This encapsulation process is enabled by the unique characteristics of CDs.

Cyclodextrin characteristics
Natural CDs are found in nature wherever starch sources, bacteria, and appropriate environmental conditions exist. The glucopyranose units of amylose starch are enzymatically restructured by bacteria such as Bacillus macerans, creating the natural CDs (Szejtli 2004). The natural CDs consist of rings of six, seven, or eight glucopyranose units named alpha, beta, and gamma, respectively (Figure 2). The glucopyranose units are attached by alpha 1–4 linkages in a circular arrangement. This arrangement creates a truncated cone that points the hydroxyl groups outward along the rims.
while directing the alpha 1–4 linkages inward (Figure 3). The narrow opening is called the primary face, and the larger opening is called the secondary face. The negatively charged hydroxyl groups lining the primary and secondary faces are responsible for the water solubility of these molecules. The interior of the CD is lined by the carbon atoms and alpha 1–4 linkages creating a lipophilic cavity. The steric nature of CDs creates a water soluble molecule that possesses a cavity capable of surrounding and binding a lipophilic molecule. The main pharmacologic benefit extracted from this structural arrangement is encapsulation of appropriately sized lipophilic molecules or drugs and the promotion of aqueous solubility (Welliver 2007).

Historically, CDs have been considered excipients (inert adjuncts) lacking pharmacologic activity but useful for improving the formulation of other active compounds (Thompson and Chaubal 2002; Loftsson et al 2005). The two key characteristics of CDs – lipophilic molecule encapsulation and aqueous solubility – have multiple beneficial applications. For example, CD encapsulation of lipophilic drugs, which are difficult to solubilize, allows their dissolution in water, which is biologically better tolerated than the organic solvents currently used, such as benzyl alcohol and propylene glycol (MacPherson 2001). The pharmacologic benefits of CD solubilization have been explored and applied successfully with many drug formulations throughout the world (Challa et al 2005). The solubilization characteristics of CDs, coupled with biological tolerance, make them desirable replacements for other organic solvents.

Although CDs possess aqueous solubility and an affinity for lipophilic molecules, the relative potency of these characteristics varies between different CDs. Close size approximation of lipophilic molecules to their corresponding CD is necessary to allow non-covalent thermodynamic interactions to occur promoting the formation of an inclusion complex. The approximate cavity sizes of the natural CDs are: gamma (0.8 nm) > beta (0.6 nm) > alpha (0.5 nm) (Welliver 2007). Once inside a CD cavity, thermodynamic attractions – including electrostatic interaction, van der Waals interaction, hydrophobic interaction, hydrogen bonding, release of conformational strain, exclusion of cavity-bound high-energy water, and charge-transfer interaction – may contribute to the formation of the inclusion complex (Liu and Guo 2002). An inclusion complex, also known as a host-guest assembly, is the newly formed molecular entity of a CD and
its encapsulated lipophilic molecule. Modification of the natural CDs allows improvement of their aqueous solubility and thermodynamic attractions for a particular guest molecule. The sites available for CD modification are on the 2nd, 3rd, and 6th carbon atoms of the glucopyranose sub-units (Figure 3). Numerous substituent atoms or groups may be placed on any or all of these sites improving a CD’s affinity for a particular molecule (Szente and Szejtli 2002). The ability to improve upon the base characteristics of natural CDs has led to the discovery of a CD that promises the unique drug effect of NMBA encapsulation with resultant termination of the paralytic effect.

**Discovery of the modified cyclodextrin sugammadex**

The impetus for discovery of the modified gamma CD sugammadex was the desire to improve the solubility of the NMBA rocuronium (Zhang 2003). Rocuronium is a non-depolarizing NMBA with a steroidal backbone that is commercially prepared in an aqueous solution adjusted to a pH of 4.0 (Rocuronium package insert 2007). Researchers at Organon Laboratories (New House, UK) wanted to solubilize rocuronium without the acidic mannitol phosphate buffer solvent used in the current formulation. A different rocuronium formulation was considered desirable in order to eliminate the acidic pH as an extraneous variable in in vitro experiments of the smooth muscle effects of rocuronium (Bom and Hope 2007). The exploration of suitable solvents led to CDs, which have been known and used to solubilize lipophilic molecules for over 100 years (Szejtli 2004).

Understanding the potential to achieve CD encapsulation specific for rocuronium, researchers explored many modifications of the alpha, beta, and gamma CDs (Adam et al 2002; Tarver et al 2002). The candidate CD chosen to solubilize rocuronium was the modified gamma CD Org 25969 (sugammadex). Sugammadex is a modified gamma CD with every 6th carbon hydroxyl group substituted with a thioether linked to a carboxyl group (Figure 4). The thioether linkages extend the cavity length allowing complete encapsulation of the rocuronium molecule while increasing the area over which thermodynamic attractions can occur (Bom et al 2002a). Many unrelated drug/CD complexes studied previously have averaged $K_s$ of $1 \times 10^4$ M$^{-1}$ to $2 \times 10^4$ M$^{-1}$ (Challa et al 2005). The discovery of sugammadex’s extremely high binding affinity for rocuronium changed the research focus from in vitro drug solubilization to the novel concept of in vivo drug extraction (Bom et al 2007). The new concept of encapsulation termination of the effects of NMBA was born.

The high lipophilic binding affinity of sugammadex raised concerns about potential undesirable binding to endogenous and exogenous steroidal compounds. These concerns were addressed during early studies. Zhang found over 40 lipophilic, steroidal, and non steroidal drugs typically given during an anesthetic case had affinities with sugammadex that ranged from 120–700 times less than that of rocuronium (Zhang 2003). These drugs include induction agents (propofol, thiopentane), narcotics (fentanyl, remifentanyl), antibiotics (vancomycin, gentamycin), bronchodilators (salbutamol, aminophylline), cardiovascular drugs (atropine, digoxin, ephedrine, phentolamine, verapamil), and steroids (cortisone, hydrocortisone) (Zhang 2003). Clinical studies also showed no evidence of interaction with or alteration of the volatile inhalation anesthetic sevoflurane or the intravenous anesthetic propofol (Vanacker et al 2007). Elsewhere, it was demonstrated that propanolol and isoprenaline did not modify the action of sugammadex (Bom and Hope 2007). Thus, sugammadex has high selectivity for the aminosteroidal NMBA.

**Mechanism of action**

Sugammadex is unique in its application, since CDs have been used to encapsulate lipophilic molecules in vitro in
order to increase solubilization for improved drug delivery. Sugammadex is the first CD created to perform its own drug effect. The process of sugammadex reversal of NMBA effects can be broken down into two component parts, direct molecular encapsulation (Figure 6) and mass extraction of NMBAs from the nicotinic junction into the plasma (Figure 7). Sugammadex is administered intravenously and remains in the plasma without diffusing or being transported to other compartments. In the plasma, sugammadex encapsulates and non-covalently binds aminosteroidal NMBAs with a one-to-one ratio. The specifics of this encapsulation process have been the focus of early studies. Using microcrystalography, Bom determined that all four steroidal rings of the rocuronium molecule lie in close approximation to the lipophilic cavity of the sugammadex molecule, with the quaternary containing ring (D) surrounded by the carboxyl groups (Bom et al 2002a). It was believed that thermodynamic interactions occurring between the sugammadex cavity and the steroidal backbone of the rocuronium molecule, along with the carboxyl groups attractions for rocuronium’s tertiary ammonium accounted for its total high binding affinity (Adam et al 2002; Zhang 2003).

The plasma encapsulation of NMBA molecules prevents their diffusion into the peripheral compartment for attachment to nicotinic ACh receptors. In addition, NMBA molecules already attached to extracellular nicotinic receptors, causing neuromuscular blockade are rapidly drawn into the plasma and encapsulated. This removal of NMBA molecules from nicotinic ACh receptors occurs because of the concentration gradient created by sugammadex binding of the NMBAs in the plasma (Epemolu et al 2003). That is, the shift to a low concentration of unbound NMBA molecules in the plasma causes the higher concentration of extracellular NMBA molecules to detach from the ACh receptors and diffuse into the plasma. Once back in the plasma, these NMBA molecules are quickly encapsulated and bound by sugammadex. This process occurs rapidly, restoring motor function.

The two-fold process of one-to-one encapsulation/binding in the plasma and the concentration gradient-mediated extraction of NMBAs from the nicotinic ACh receptors results in fast and effective termination of neuromuscular blockade by sugammadex. The ability of sugammadex to encapsulate and reverse the effects of aminosteroidal NMBAs varies between agents. Sugammadex reverses rocuronium greater than vecuronium and much greater than pancuronium (Alvarez-Gomez et al 2007; Decoopman et al 2007; Duvaldestin et al 2007).

**Preclinical studies**

An overview of the research shows the development and progression of a safe and efficacious reversal drug that is poised to enable dramatic improvements in the management of neuromuscular blockade. Animal studies confirmed the high affinity of sugammadex for both rocuronium and vecuronium and, to a lesser extent, pancuronium with the ability to terminate NMBA effects under multiple conditions. (Welliver 2006). Mason successfully reversed rocuronium- and vecuronium-induced
neuromuscular blockade in guinea pigs with sugammadex 1 mg/kg in less than 1 minute (Mason and Bom 2001). Profound neuromuscular block induced by rocuronium 500 µg/kg in Rhesus monkeys was successfully performed by de Boer using 2.5 mg/kg sugammadex (de Boer et al 2006).

Clinical studies
Phase I studies
Human studies of sugammadex were first performed by Gijsenbergh in 29 healthy male volunteers. All were anesthetized and had neuromuscular blockade induced by rocuronium. Either placebo or sugammadex, in doses ranging from 0.1–8.0 mg/kg, were given, and both time and degree of reversal were recorded. Sugammadex 8.0 mg/kg reversed rocuronium-induced blockade in 1 minute, compared to 52 minutes with placebo. The investigators concluded that effective and safe reversal of rocuronium-induced neuromuscular blockade could be achieved with sugammadex. (Gijsenbergh et al 2005).

Phase II studies
A phase II study also demonstrated safe reversal of rocuronium-induced neuromuscular blockade of 2 hours or greater duration (Shields et al 2006). In this study of 30 anesthetized patients age >18 years, ASA class I-III, sugammadex was administered at doses of 0.5–6.0 mg/kg. At doses of 1.0 mg/kg and above, sugammadex effectively reversed the effects of rocuronium in a dose-dependent fashion within 4 minutes (Shields et al 2006). Two studies in 87 patients age 18–87 years, ASA class I-III, explored the use of sugammadex for reversal of high-dose rocuronium (1.0 and 1.2 mg/kg) (Khunl-Brady et al 2005; Rex et al 2005). Sugammadex (2–16 mg/kg) was administered at 3 and 15 minutes after rocuronium administration. The average time to reversal (TOF 0.9) with 8.0 mg/kg sugammadex was <3 minutes at both time intervals with both doses of rocuronium. It was concluded that there was a clear dose-response relationship in terms of time to recovery with sugammadex (Khunl-Brady et al 2005; Rex et al 2005) de Boer also found profound rocuronium-induced (1.2 mg/kg) neuromuscular blockade given with propofol and opioid anesthesia of greater than 90 minutes duration was effectively reversed by sugammadex in a dose dependent manner in 45 patients aged 18–64 years, ASA class I-II (de Boer et al 2007).

Studies of sugammadex for the reversal of shallow vecuronium-induced neuromuscular blockade have also shown a dose-dependent time to full reversal. Puhringer reversed both vecuronium- and rocuronium-induced neuromuscular blockade in 100 patients, age 20–65 years, ASA class I-III (Puhringer et al 2007). Sugammadex doses of...
2.0 mg/kg for rocuronium and 4.0 mg/kg for vecuronium effectively reversed shallow neuromuscular blockade (TOF 2/4) in 3 minutes or less. In another study, profound vecuronium-induced neuromuscular blockade (PTC 1–2) was effectively reversed by sugammadex 4.0 mg/kg in an average time of 4.5 minutes (Lemmens et al 2007). Dose-dependent reversal of both rocuronium- and vecuronium-induced profound neuromuscular blockade by sugammadex was also observed by Duvaldestin in a study of 102 patients, age 21–64 years, ASA class I-III (Duvaldestin et al 2007). Sugammadex 2.0 mg/kg reversed profound rocuronium-induced neuromuscular blockade (PTC 1–2) in 3.5 minutes or less, while a greater dose of 4.0 mg/kg was required to reverse vecuronium-induced profound neuromuscular blockade within the same amount of time.

In addition to the intermediate duration NMBAs rocuronium and vecuronium, the effects of the long acting NMA pancuronium have also been successfully reversed by sugammadex (Decoopman et al 2007). In this study of 20 patients, age 20–81 years, ASA class I-III, shallow (TOF 2/4) pancuronium-induced neuromuscular blockade was effectively reversed in less than 3 minutes with a sugammadex dose of 4.0 mg/kg. The authors concluded that sugammadex had a “good safety profile”. Interestingly, a significant dose-response relationship was not shown in this study. The effectiveness of sugammadex for the reversal of pancuronium, in addition to rocuronium and vecuronium, is significant in light of the limitations of cholinesterase inhibitors.

The efficacy of sugammadex for the reversal of neuromuscular blockade has been compared to that of the cholinesterase inhibitor reversal drugs neostigmine and edrophonium. In one study the speed and effectiveness of sugammadex (4.0 mg/kg) for reversal of profound vecuronium-induced neuromuscular blockade (PTC 1–2) was compared to that of neostigmine (70 µg/kg) (Lemmens et al 2007). With neostigmine, the average reversal time to a TOF ratio of 0.9 was 66.2 minutes compared to an average time of 4.5 minutes with sugammadex. Another study comparing sugammadex (4.0 mg/kg) and neostigmine (70 µg/kg) for reversal of profound rocuronium-induced neuromuscular blockade (PTC 1–2) also observed a much faster return to a TOF ratio of 0.9 with sugammadex (2.9 minutes) than neostigmine (50.4 minutes) (Jones et al 2007).

The results of these phase II clinical studies have consistently demonstrated that sugammadex achieves fast and effective reversal of various degrees and durations of rocuronium- and vecuronium-induced neuromuscular blockade. Shallow pancuronium-induced neuromuscular blockade has also been effectively reversed (Decoopman et al 2007). Comparisons with cholinesterase inhibitors have shown faster and more thorough reversal accomplished with sugammadex with an improved safety profile (Lemmens et al 2007; Jones et al 2007).

**Phase III studies**

In a phase III study in 100 patients, Alvarez-Gomez reported faster reversal of vecuronium using sugammadex 2.0 mg/kg compared to neostigmine 50 µg/kg (Alvarez-Gomez et al 2007). The median time for reversal of shallow (TOF 2/4) vecuronium-induced neuromuscular blockade to a recovery of 0.9 TOF ratio was 2.1 minutes for sugammadex and 18.9 minutes for neostigmine. In another study, reversal of moderately profound rocuronium-induced neuromuscular blockade was also found to be faster with sugammadex 4.0 mg/kg (average 1.78 minutes) verses edrophonium-atropine (average 5.51 minutes) and neostigmine-glycopyrrolate (average 17.4 minutes) (Sacan et al 2007). All patients reversed with sugammadex achieved full reversal to a TOF ratio of 0.9. Only 10% of the edrophonium-atropine reversed patients and 25% of the neostigmine-glycopyrrolate reversed patients achieved full reversal within 30 minutes. Interestingly, all patients were able to perform a 5-second head lift after all reversal drugs. The sugammadex group experienced significantly lower incidences of increased heart rate and dry mouth.

Additional comparison of sugammadex to conventional cholinesterase inhibitor reversal therapy has demonstrated a faster time to full reversal of rocuronium- and vecuronium-induced neuromuscular blockade by sugammadex. In a study with 98 patients age >18 years, ASA class I-III, sugammadex was compared to neostigmine reversal (Blobner et al 2007). Sugammadex 2.0 mg/kg or neostigmine 50 µg/kg along with glycopyrrolate 10 mcg/kg was administered at a TOF 2/4. The mean time to full reversal was 1.4 minutes for sugammadex and 17.6 min for neostigmine. Flockton compared sugammadex reversal of rocuronium effects to neostigmine reversal of the benzyl isoquinoline NMBAs cis-attracurium. Sugammadex 2.0 mg/kg was delivered at TOF 2/4 after rocuronium 0.6 mg/kg in 34 patients. Neostigmine 50 mcg/kg along with glycopyrrolate 10 µg/kg was delivered at TOF 2/4 after cis-attracurium 0.15 mg/kg in 39 patients. The mean time to full reversal was 1.51 minutes for sugammadex compared to 2.85 minutes for neostigmine (Flockton et al 2007).

Phase III clinical trials have also explored the effects of sugammadex in pediatric and elderly patients, and in patients with renal, pulmonary, and cardiac disease. A study by Plaud
investigated rocuronium-induced (0.6 mg/kg) neuromuscular blockade in 8 infants (age 28 days to 23 months), 24 children (age 2–11 years), 31 adolescents (age 12–17 years), and 28 adults (age 18–65 years) anesthetized with propofol and opioids or caudal anesthesia (Plaud et al 2007). When shallow neuromuscular block was confirmed by TOF 2/4, sugammadex doses of 0.5–4.0 mg/kg were administered. A dose-dependent time to TOF ratio 0.9 was demonstrated in all groups except the infant group due to the low number of subjects. The median time to recovery was less than 3 minutes with sugammadex doses of 1.0, 2.0, and 4.0 mg/kg in all groups.

The efficacy of sugammadex for the reversal of shallow rocuronium-induced neuromuscular blockade (TOF 2/4) was studied in 48 adult patients (age 18–64 years), 62 elderly (age 65–74 years), and 40 old elderly patients (age >75 years) (McDonagh 2007). All patients received rocuronium 0.6 mg/kg followed by sugammadex 2 mg/kg at a TOF 2/4. The mean time to recovery of the TOF ratio to 0.9 was 2.3 minutes in the adult group, 2.6 minutes in the elderly group, and 3.6 minutes in the old elderly group. The estimated time to TOF 0.9 in all patients over 65 years of age was 2.9 minutes versus 2.3 minutes in the adult group, a statistically significant difference (p = 0.022).

The effectiveness of sugammadex for the reversal of rocuronium-induced neuromuscular blockade was assessed in 15 patients with impaired renal function (creatinine clearance <30 mL/min) and 15 patients with normal renal function (creatinine clearance >80 mL/min) (Staals et al 2007). All patients were anesthetized with propofol and opioids, and had neuromuscular blockade induced with rocuronium 0.6 mg/kg. At the reappearance of TOF 2/4, sugammadex 2.0 mg/kg was administered. The mean time to recovery of TOF ratio to 0.9 was 2.0 minutes in the renal impaired group and 1.7 minutes in group with normal renal function. The authors reported no signs of recurarization or adverse effects, and concluded that sugammadex rapidly and completely reverses rocuronium-induced neuromuscular blockade in patients with normal or impaired renal function.

Patients with pulmonary disease were studied to examine the possible respiratory effects of sugammadex. Seventy-seven patients 18 years or older, ASA class II-III, with a known history or diagnosis of pulmonary disease were anesthetized and administered rocuronium (0.6 mg/kg) (Amao et al 2007). At the end of surgery and reappearance of TOF 2/4, sugammadex 2.0 or 4.0 mg/kg was administered. The mean time to recovery of the TOF ratio to 0.9 was 1.8 minutes in the sugammadex 4.0 mg/kg group, and 2.1 minutes for the 2.0 mg/kg group. Two serious episodes of bronchospasm occurred that were considered possibly related to sugammadex, both of which were in the 4.0 mg/kg dose group. Both patients had a history of asthma. No alterations in respiratory rate or recurarization were observed in any patients. The authors concluded sugammadex was well tolerated and effective for the reversal of rocuronium-induced neuromuscular blockade in patients with pulmonary disease.

One hundred twenty-one patients with cardiac disease (NYHA class II-III, ASA class II-IV, age 36–90 years) undergoing elective non-cardiac surgery, were anesthetized and administered rocuronium (Dahl et al 2007). At the reappearance of TOF 2/4, sugammadex 2.0 or 4.0 mg/kg was administered. The mean time to a TOF ratio of 0.9 was found to be 1.7 minutes with sugammadex 2.0 mg/kg and 1.4 minutes with the 4.0 mg/kg dose. The authors disclosed two serious adverse events (SAEs) relating to prolongation of the QTc interval in the placebo and sugammadex groups. “Of these, one case of QTc interval prolongation in each treatment group (placebo and sugammadex group) was considered by the investigator to be possibly related to study treatment”. Analysis of the mean QTc interval using the Fridericia correction (US Dept HHS 2005) was performed. Safe and effective use of sugammadex in cardiac patients was concluded. However, the general anesthetics used in this study, which may cause QTc prolongation, were not disclosed in this preliminary report.

**Reported adverse effects**

Few adverse effects have been attributed to sugammadex. One study reported abdominal discomfort as “definitely related” to study drug (Suy et al 2007). Movement after sugammadex was observed in several studies which may be expected with rapid restoration of motor function and lighter anesthetic levels towards the conclusion of surgery (Sorgenfrei et al 2006; de Boer et al 2007). Possible adverse effects reported in clinical trials include: erythema, alterations in taste and smell, coughing, dry mouth, tachycardia, bradycardia, pyrexia, dizziness, vomiting, hypotension, abnormal urine levels of N-acetyl-glucosaminidase, and QT interval prolongation (Gjensbergh et al 2005; Shields et al 2006; Sorgenfrei et al 2006; Dahl et al 2007). QT prolongation was first observed by Rex but was considered not to be related to sugammadex (Rex et al 2005). An analysis by Vanacker determined that corrected QT prolongations, which were not arrhythmogenic, were likely to be due to the anesthetics sevoflurane and propofol (Vanacker et al 2007). A study by de Kam using the criteria of the International Conference on Harmonisation.
Sugammadex sodium (ICH-E14) guidelines (Shah 2005) found that sugammadex doses up to 32 mg/kg were not associated with QT/QTc prolongation (de Kam et al 2007). The authors of a study in cardiac patients also reported that no QTc prolongations were related to sugammadex (Dahl et al 2007).

Inadvertent overdose occurred in one clinical study, when sugammadex 40 mg/kg was administered instead of 4.0 mg/kg, but this was not associated with any adverse effects and effective reversal of rocuronium was reported. (Molina et al 2007) Although most disclosed adverse effects have been expressed as only “possibly related” to the study drug, conclusive determination has yet to be made. It should be noted that some phase III studies have not been completed at the time of writing, and unknown side effects may exist. The results from one comparative study suggested that “the safety profile of sugammadex was at least as good as that of neostigmine” (Jones et al 2007).

Metabolism and excretion
Sugammadex is biologically well tolerated. It does not undergo metabolism or breakdown and therefore does not affect blood sugar levels. It is excreted by the kidneys intact and has been found to increase the excretion of rocuronium molecules that it encapsulates (Sorgenfrei et al 2006). The renal excretion of sugammadex mirrors glomerular filtration rate (Gijsenbergh et al 2005) and it can be removed by dialysis (Hartman et al 2007).

Clinical implications of direct acting reversal by encapsulation
Intraoperative
The ability to reverse NMBAs directly and completely will allow the provision of continual profound neuromuscular blockade that may currently be inadvisable due to the limitations of cholinesterase inhibitor reversal agents. Multiple surgical specialties are likely to find this beneficial. With incomplete neuromuscular blockade, surgeons may encounter unnecessary difficulties. For example, those who require open access to abdominal cavities may struggle with retractors to improve visualization of structures. Others may find patient extremities resistant to manipulation.

Patient attempts at spontaneous ventilation are evidence of incomplete neuromuscular blockade. Diaphragmatic excursion represents significant return of neuromuscular function and closely correlates with motor function return of the abdominal rectus muscles. Motor function disrupts on optimal exposure and causes displacement of abdominal viscera. In contrast, profound neuromuscular blockade assures no diaphragmatic movement or abdominal rectus tone, and optimizes surgical access. Consistent profound neuromuscular blockade may also allow access through smaller incisions as muscular tension and contractions are eliminated as surgical hindrances.

Laparoscopic procedures are assisted by assured patient immobility, as coughing or “bucking” under anesthesia increases the risk of organ injury and interferes with video imagining. Fracture reductions and manipulation of extremities may also be conducted with greater ease and speed in the absence of muscular tone or resistance. With the availability of sugammadex, surgical procedures requiring profound neuromuscular block may be accomplished without the risks associated with incomplete reversal by cholinesterase inhibitors. That is, by means of its rapid and complete reversal of rocuronium and vecuronium, sugammadex will allow surgeons to operate with profound neuromuscular blockade up to and including wound closure.

Neuromuscular monitoring
In light of the effectiveness of SRBAs, the question of continued use of neuromuscular monitoring has been raised (Kopman 2006; Naguib 2007). Neuromuscular monitoring should be used whenever neuromuscular blocking agents are administered. In the interests of improving vigilance, and because of concerns about potentially insufficient sugammadex doses, we suggest the continued use of nerve stimulators to assess the degree of neuromuscular blockade. Eleveld described a scenario in which initial recovery to a TOF ratio of 0.9 quickly deteriorated to <0.3 due to an insufficient dose of sugammadex (0.5 mg/kg) delivered for the reversal of profound rocuronium-induced neuromuscular blockade in a dose-finding study (Eleveld et al 2007). Consistent and effective dosages based on degree of blockade will be determined, however, individual variability and under-dosing may allow recurarization such as that reported by Eleveld. Clinical assessment and neuromuscular monitoring should remain a mainstay of anesthesia practice (Eriksson 2003).

Summary
An opportunity is emerging that will allow profound neuromuscular blockade during surgery with full and immediate reversal upon conclusion. Reversal of neuromuscular blockade with the novel agent sugammadex is likely to increase the speed of patient recovery from anesthesia and improve time to discharge. Delivery of a safer, more effective drug
for reversal of NMBA will also provide additional benefits. For example, the assurance of full reversal of neuromuscular blockade will allow improved conditions for surgery and, possibly, improved patient recovery. The rapid return of neuromuscular function achieved by sugammadex may also facilitate rapid sequence intubation using the nondepolarizing NMBA rocuronium, and play a role in the management of the “cannot intubate, cannot ventilate scenario. Rescue of residual paralysis resulting from incomplete reversal by cholinesterase inhibitors may also be performed quickly. Differential diagnosis of low level residual paralysis versus other compromising factors may also be achieved with sugammadex.

Patient outcome studies comparing conventional NMBA reversal with cholinesterase inhibitors to reversal by means of CD encapsulation are needed to determine the potential benefits of sugammadex beyond effective and immediate NMBA reversal. Complete control of neuromuscular blockade with immediate reversibility will allow anesthetists to offer surgeons optimal conditions that are not always achieved at present. A full appreciation of SRBA pharmacology will become known with continued clinical study, but, the successful outcomes of studies to date appear to be heralding in a new era in neuromuscular blockade management.

References
Blobner M, Eriksson L, Scholz J, et al. 2007. Sugammadex 92.0 mg/kg significantly faster reverses shallow rocuronium-induced neuromuscular blockade compared with neostigmine (50 mg/kg). Eur J Anaesthesiol, 24(Suppl 39):125.


